MASAYA MATSUMOTO

President and CEO
TWOCELLS company limited

In 2012, Masaya has joined TWOCELLS and got involved in the research and development of regenerative medicine products including "gMSC®1," an allogeneic cartilage regeneration product using serum-free culture media (STK® series) and mesenchymal stem cells (MSCs). During this period, he has promoted the construction of a cell bank of MSCs for the purpose of clinical trials and commercial uses in collaboration with Osaka University, which was a pioneering project in Japan.

Since 2016, he had overseen the company's Phase 3 clinical trial of gMSC®1.
From 2020 to 2023, he was appointed as Director (Clinical Development) and also developed subsequent pipelines, including gMSC®2 for stroke and gMSC®4 for chronic kidney disease.
He was appointed President and CEO of TWOCELLS in November 2023.

Masaya has graduated Hiroshima Univ. and received Ph.D. (Health Science).